Analysts revised the average one-year price target for Immunic, Inc. to $44.09 per share. This figure represents a 13.34% decrease from the previous estimate of $50.87. Current analyst targets for the stock range from a low of $19.19 to a high of $89.25.
Despite the downward revision, the new average target suggests a potential 245.24% upside from the recent closing price of $12.77.
Institutional interest in Immunic increased during the last quarter. The number of funds or institutions reporting positions in the company grew by 15.38%.